DEA agent to FDA safety panel: Hydrocodone combos are 'killing us'
This article was originally published in Scrip
Drug safety advisers to the US FDA heard arguments from both ends of the spectrum on 24 January about the impact to patients and society if hydrocodone combination medicines, like Vicodin (acetaminophen-hydrocodone), are moved from Schedule III to the more restrictive Schedule II – or "up-scheduled" – under authorities granted to the agency by the 1970 US Controlled Substances Act (CSA).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.